PMC:7558914 / 22432-22655
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 536 | 86-94 | Species | denotes | patients | Tax:9606 |
| 543 | 38-49 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 555 | 100-108 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 556 | 121-130 | Disease | denotes | pneumonia | MESH:D011014 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T39 | 121-130 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T145 | 0-223 | Sentence | denotes | Several randomized clinical trials on tocilizumab, either alone or in combination, in patients with COVID-19 with severe pneumonia are underway, and its use was included in the Chinese national treatment guidelines [30,31]. |